Study of regulating effect of resveratoral on C-myc gene in human small cell lung cancer H446 cells

doi:10.3877/cma.j.issn.1674-6902.2020.02.005

Abstract

Abstract:

Objective

The aim of the present study was to evaluate the effects of resveratrol on C-myc gene expression in small-cell lung cancer (SCLC) cell.

Methods

The H446 cell line of human small-cell lung cancer was used as the object of this study. The expression levels of C-myc were measured by western blot analysis and Real-time PCR in H446 cells treated with various concentrations of Res for 24 h and treated with the same concentration Res at different times. Cisplatin was used as the intervention for effect verification.

Results

The measure results of Western blot and Real-time PCR show that resveratrol has regulating effect on the expression of C-myc in H446 cells of human small-cell lung cancer. Along with the extension of the action time and the increase of the concentration, the expression of c-myc further decreased. These effects have the characteristic of concentration-and time-dependence, the difference has statistically significant (P<0.05). In addition, combined treatment with NAC and Res is found to be a inhibiting effect compared with either monotherapy while cisplatin and Res is found to be markedly more effective compared with either monotherapy, the difference has statistically significant (P0.05). However, the result of Western blot shows that the expression of C-myc in the cytonuclear protein has no significant difference in the combination group and the resveratrol group (P>0.05).

Conclusion

The present study demonstrated that resveratrol has a significant effect on C-myc expression in H446 cells. These findings suggest that the inhibiting effect of resveratrol on small cell lung cancer may be related to myc gene.

Key words: Resveratrol, H446 cells, Small cell lung cancer, Myc gene

Wangping Li, Lijie Ma, Lei Pan, Faguang Jin. Study of regulating effect of resveratoral on C-myc gene in human small cell lung cancer H446 cells[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 148-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.02.005

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I02/148

Figures/Tables 5

References 31

1	Hsieh TC, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule[J]. Biofactors, 2010, 36: 360-369.
2	Schnekenburger M, Dicato M, Diederich M. Plant-derived epigenetic modulators for cancer treatment and prevention[J]. Biotechnol Adv, 2014, 32: 1123-1132.
3	Chan S, Kantham S, Rao VM, et al. Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer's disease[J]. Food Chem, 2016, 199: 185-194.
4	Blanquer-Rosselló MD, Hernández-López R, Roca P, et al. Resveratrol induces mitochondrial respiration and apoptosis in SW620 colon cancer cells[J]. Biochim Biophys Acta, 2017, 861: 431-440.
5	Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives[J]. Cancer Lett, 2008, 269: 243-261.
6	Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms[J]. Arch Biochem Biophys, 2009, 486: 95-102.
7	Goswami SK, Das DK. Resveratrol and chemoprevention[J]. Cancer Lett, 2009, 284: 1-6.
8	Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1): 22-35.
9	Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010, 463(7283): 899-905.
10	Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment[J]. Signal Transduct Target Ther, 2018, 3(1): 5.
11	Wangping Li, Yun Shi, Ruixuan Wang, et al. Resveratrol promotes the sensitivity of small cell lung cancer H446 cell lines to cisplatin via mitochondrial apoptotic pathway[J]. Int J Oncol, 2018, 53: 2123-2130.
12	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
13	Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine[J]. Pers Med, 2014, 11(3): 309-321.
14	Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes[J]. Science, 1997, 275(5297): 218-220.
15	Llijie Ma, wangping Li, ruixuan Wang, et al. Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis[J]. Int J Oncol, 2015, 47(4): 1460-1468.
16	Dang CV. MYC on the path to cancer[J]. Cell, 2012, 149(1): 22-35.
17	Meyer N, Penn LZ. Reflecting on 25 years with MYC[J]. Nat Rev Cancer, 2008, 8(12): 976-990.
18	Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins[J]. Nat Rev Mol Cell Biol, 2005, 6(8): 635-645.
19	George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer[J]. Nature, 2015, 524(7563): 47-53.
20	Semenova EA, Nagel R, Berns A, et al. Origins, genetic landscape，and emerging therapies of small cell lung cancer[J]. Genes Dev, 2015, 29(14): 1447-1462.
21	Helfrich BA, Kim J, Gao DX, et al. Barasertib(AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo[J]. Mol Cancer Ther, 2016, 15(10): 2314-2322.
22	Malynn BA, de Alboran IM, O′Hagan RC, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation[J]. Genes Dev, 2000, 14(11): 1390-1399.
23	Di Giacomo S, Sollazzo M, Paglia S, et al. MYC, cell competition，and cell death in cancer[J]. Genes, 2017, 8(4): 668-679.
24	Lu Q, Hong W. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells[J]. Cell Signal, 2009, 21(7): 1054-1059.
25	Noujaim D, van Golen CM, van Golen KL, et al. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells[J]. Oncogene, 2002, 21(29): 4549-4557.
26	李王平，马李杰，潘　蕾，等. 白藜芦醇诱导小细胞肺癌H446细胞凋亡机制的研究[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(1): 15-23.
27	van Golen CM, Soules ME, Grauman AR, et al. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells[J]. Oncogene, 2003, 22(17): 2664-2673.
28	van Golen CM, Castle VP, Feldman EL. IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma[J]. Cell Death Differ, 2000, 7(7): 654-665.
29	Lee MW, Kim DS, Kim HR, et al. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL[J]. Cell Prolif, 2019, 52(3): e12577.
30	Lu KV, Jong KA, Rajasekaran AK, et al. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line[J]. Lab Invest, 2004, 84(1): 8-20.
31	Grotzer MA, Castelletti D, Fiaschetti G, et al. Targeting Myc in pediatric malignancies of the central and peripheral nervous system[J]. Curr Cancer Drug Targets, 2009, 9(2): 176-188.

[1]	Hong Ye, Jingzhe Lyu, Liangjun Zhong. New study progress of resveratrol in the treatment of periodontitis and diabetes [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 376-380.
[2]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[3]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[4]	Rongrong Ma, Zongjuan Ming, Wei Li, Dexin Zhang, Shuanying Yang. Characteristics and mechanism of pathological transformation of lung adenocarcinoma [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(06): 782-786.
[5]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[6]	Dong Wei, Yunchao Xin, Bo Liu, Yu Rong, Yanming Li, Yanbing Hao. Predictive value of PROX1 for recurrence after minimally invasive resection of early non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(04): 494-497.
[7]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[8]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[9]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[10]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[11]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[12]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[15]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.

Please choose a citation manager

Content to export